Thrilled to share our recent work in @CellCellPress ✨
We study the extent to which tumor suppressor genes in cancer adhere to Knudson's ‘two-hit’ hypothesis, and their clinical implications. 🧵👇
Also a detailed 🧵 by @EdReznik below:
@MSKPathology@MSKCancerCenter
A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in @CellCellPress. With Mark Zucker, Maria Perry, and Chai Bandlamudi cell.com/cell/fulltext/S0092…
MSK-IMPACT is truly the gift that keeps on giving!
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors (!!)
cell.com/cancer-cell/fulltex…
"One-third of all drivers arose in non-canonical contexts"
Congratulations @MFBerger1@DSolit & team.
1. Tertiary Lymphoid Structures (TLSs) – on demand lymphoid aggregates that assemble in inflamed tissues/cancer to regulate immunity
But how? What molecule triggers? What cells induce?
TODAY in @Naturenature.com/articles/s41586-0…
Long-term #PDAC survivor PART4 – TLSs
🧵1/25
Something I've observed in academia but I suspect is true in industry as well: as you become more senior, you'll find that you can be much more productive if you spend all your time being a manager and letting junior people do all the real work. But after a few years of this, you're likely to lose your skill at doing the work yourself, the opportunity to practice that skill, and the gratification of doing so that drew you to your chosen profession in the first place. And you'll probably also get worse at being a manager as you lose touch with the actual work.
Avoiding managerdom is hard. You have to give up substantial short-term productivity gains. If you're in academia in a tenure track, you risk not getting tenure by being less productive. And personally I find that switching between thinker mode (deep work with no distractions for a whole day) and manager mode (a thousand quick but urgent tasks) to be highly unpleasant. When I'm in thinker mode, it kills me that people have to wait a day (often a lot more) for a 1-minute response from me that could unblock them on what they're stuck on and save them hours of work. When I'm in manager mode, it kills me that I have all these creative ideas sloshing around in my brain that I'm not able to execute on.
So it's extremely tempting to perpetually be in just one mode or the other. When you have a team, not managing them is not an option, but being a pure manager is an option. That makes a constant struggle to carve out time for your own work and not give in to the temptation.
Note: I think this is only tangentially related to Founder Mode vs Manager Mode. It's much more related to another Paul Graham essay, Maker's Schedule vs Manager's Schedule. And Deep Work by Cal Newport is very relevant.
And, thankful to mentors, colleagues and collaborators for stimulating discussions.
@DSolit, @MFBerger1, @nikolausschultz, @MLadanyi, Sarat Chandarlapaty, @AdamJSchoenfeld, @YoninaMG, and many others.
And, most importantly, grateful to our patients for enabling this work 🙏 /F
Amazing work by co-first authors Mark Zucker and Maria Perry.
And an absolute pleasure and joy to work and think alongside the brilliant @EdReznik. /10
Overall, our findings suggest that zygosity of TSG muts matter, and is a poorly recognized biomarker in solid tumors. (Btw, for oncogenes too. Coming soon!)
This highlights the importance of inferring and reporting allele-specific copy number in clinical reports.
#MSKIMPACT /9
These findings are particularly meaningful given recent work by @FSkoulidis and J.Heymach showing that KEAP1-mutated lung adenocarcinoma pts derived particular clinical benefit from dual ICB compared to PD-L1 inhibitor alone. #PredictiveBiomarkernature.com/articles/s41586-0…
/8
KEAP1 stood out as it is also a well-known prognostic biomarker in LUAD.
So, we asked if the outcomes to standard of care Tx in LUAD also differed by KEAP1 zygosity.
Indeed they did!
Only KEAP1 biallelic but not monoallelic patients had shorter PFS.
🙏@AdamJSchoenfeld /7
But, does TSG zygosity matter for patient outcomes?
It appears it does.
For several TSGs, we find that zygosity is strongly associated with overall survival (OS). These include Class 1 (TP53, PTEN, KEAP1, etc) as well as Class 2 (eg: SMARCA4) genes. /6
We also highlight several ways in which patterns for selection for two-hits can be used to increase focus on TSGs mutated in non-canonical cancers or re-prioritize VUSs (see paper).
Thanks to the exceptional contribution and creativity from Sam Gould and @fjsanchezrivera 🙏/5
The most interesting group of TSGs were Class 2 (eg: ATM, ARID1A, etc) which are mutated in 1 in 5 cancers. These genes showed context-specific patterns of selection for biallelic losses, and thus providing a rich substrate for future work in understanding their function. /4